PATENT
Our Asset
Our Asset
| Patent Title | Registration / Application No. | Date Held |
|---|---|---|
| Method for Site-Selective High-Efficiency Fluorescent Labeling of Target Proteins | 10-1957979 | April 2022 |
| Method for High-Efficiency Fluorescent Labeling of Target Proteins Using Purified Fluorescent Methionine and Eukaryotic Cell-Free Translation System | 10-1971467 | May 2022 |
| Fusion Protein Containing Foot-and-Mouth Disease Virus-Derived Epitope and Virus-Like Particle Containing the Same | 10-2022859 | December 2023 |
| Fusion Protein Containing Pathogen-Derived Antigen and Virus-Like Particle Containing the Same | 10-1861578 | December 2023 |
| H5 Avian Influenza Virus-Like Particle Vaccine and Method for Producing the Same | 10-1906457 | December 2023 |
| Target Protein Expression Platform Using Viral Nucleocapsid | 10-2617593 | February 2025 |
| Pentameric Toxin Protein-Based Target Protein Fusion Pentamer Manufacturing Platform Using Viral Nucleocapsid | 10-2677201 | January 2025 |
| Crystalline Protein-Based Target Protein Fusion Self-Assembling Nanoparticle Manufacturing Platform Using Viral Nucleocapsid | 10-2617592 | December 2024 |
| Pentamer-Based Fusion Protein Containing WHEP Domain and System for Expressing the Same | 10-2022-0062792 | December 2024 |
| Influenza B Vaccine | 10-1888751 | October 2024 |
| Compounds for Treating Diseases Caused by Coronavirus Infection | 10-1913789 | November 2024 |
| Patent Title | Registration / Application No. | Filing Date | Category |
|---|---|---|---|
| Target Protein Expression Platform Using Viral Nucleocapsid | PCT/KR2023/006958 | 2023-05-23 | PCT |
| Crystalline Protein-Based Target Protein Fusion Self-Assembling Nanoparticle Manufacturing Platform Using Viral Nucleocapsid | PCT/KR2023/006959 | 2023-05-23 | PCT |
| Pentameric Toxin Protein-Based Target Protein Fusion Pentamer Manufacturing Platform Using Viral Nucleocapsid | PCT/KR2023/006961 | 2023-05-23 | PCT |
| Target Protein Expression Platform Using Viral Nucleocapsid | 18/723,423 | 2024-06-22 | US |
| Crystalline Protein-Based Target Protein Fusion Self-Assembling Nanoparticle Manufacturing Platform Using Viral Nucleocapsid | 18/868,102 | 2024-11-21 | US |
| Pentameric Toxin Protein-Based Target Protein Fusion Pentamer Manufacturing Platform Using Viral Nucleocapsid | 18/867,804 | 2024-11-21 | US |
| Target Protein Expression Platform Using Viral Nucleocapsid | 23812102.4 | 2024-06-05 | EP |
| Crystalline Protein-Based Target Protein Fusion Self-Assembling Nanoparticle Manufacturing Platform Using Viral Nucleocapsid | 23812103.2 | 2024-12-12 | EP |
| Pentameric Toxin Protein-Based Target Protein Fusion Pentamer Manufacturing Platform Using Viral Nucleocapsid | 23812104.0 | 2024-12-12 | EP |
| Target Protein Expression Platform Using Viral Nucleocapsid | 2023800158934 | 2024-06-28 | CN |
| Crystalline Protein-Based Target Protein Fusion Self-Assembling Nanoparticle Manufacturing Platform Using Viral Nucleocapsid | 202380055824.6 | 2025-01-22 | CN |
| Pentameric Toxin Protein-Based Target Protein Fusion Pentamer Manufacturing Platform Using Viral Nucleocapsid | 202380055823.1 | 2025-01-22 | CN |
| Target Protein Expression Platform Using Viral Nucleocapsid | 2024-534171 | 2024-06-05 | JP |
| Crystalline Protein-Based Target Protein Fusion Self-Assembling Nanoparticle Manufacturing Platform Using Viral Nucleocapsid | 2024-569232 | 2024-11-22 | JP |
| Pentameric Toxin Protein-Based Target Protein Fusion Pentamer Manufacturing Platform Using Viral Nucleocapsid | 2024-569238 | 2024-11-22 | JP |
| Target Protein Expression Platform Using Viral Nucleocapsid | 1-2024-02678 | 2024-04-12 | VN |
| Crystalline Protein-Based Target Protein Fusion Self-Assembling Nanoparticle Manufacturing Platform Using Viral Nucleocapsid | 1-2024-09528 | 2024-12-20 | VN |
| Pentameric Toxin Protein-Based Target Protein Fusion Pentamer Manufacturing Platform Using Viral Nucleocapsid | 1-2024-09527 | 2024-12-20 | VN |
Vaxdigm Co., Ltd.
CEO Sung Jae Kim
TEL 02-6205-2550
EMAIL hydrogold@vaxdigm.com
BUSINESS NUMBER 657-87-02464
ADDRESS 412ho, 201, Songpa-daero, Songpa-gu, Seoul, Republic of Korea
PRIVACY POLICYㅣTERMS AND CONDITIONS
COPYRIGHT © 2026 VAXDIGM. ALL RIGHTS RESERVED.
Vaxdigm Co., Ltd.
CEO Sung Jae Kim
EMAIL hydrogold@vaxdigm.com ㅣ TEL 02-6205-2550
BUSINESS NUMBER 657-87-02464 ㅣ ADDRESS 412ho, 201, Songpa-daero, Sonpa-gu, Seoul, Republic of Korea
PRIVACY POLICYㅣTERMS AND CONDITIONS
COPYRIGHT © 2026 VAXDIGM. ALL RIGHTS RESERVED.
